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ABSTRACT 
The development of more effective cancer therapeutic strategies are still critically 
required. The maximization of the therapeutic effect in combination with avoiding the 
severe side effects on normal tissues when using chemotherapy drugs is still an urgent 
problem that requires improvements urgently. Here we provide implantable and 
controllable drug-release that utilises silk fibroin (SF) as a nanofibrous drug delivery 
system (DDS) for cancer treatment. A nanofibrous structure with controllable fibre 
diameter (<100 nm) was produced. The drug release rate of the SF DDS was 
controlled by applying a post-treatment process. In vitro anti-cancer (HCT116) results 
indicated that curcumin (CM)-SF nanofibrous matrix had a superior anti-cancer 
potential when the concentration was >5 μg/mL. The mechanism could be explained 
by the cell cycle being held in the S phase. The toxic effect on normal cells (NCM460) 
was minimized by using a treatment concentration range (5-20 μg/mL). Implantation 
of this DDS into the tumour site inhibited the growth of solid tumour; this offers an 
alternative approach for novel cancer therapy. 
Keywords: Silk; drug delivery system; smart treatment; cancer 
1. Introduction 
Cancer is the leading cause of death in developed countries and the second most 
life-threatening disease in developing countries. Statistics from 2012 state there were 
14.1 million new cases of cancer and 8.2 million of deaths in the world (Cancer 
Research UK). More than 50% of patients die of cancers due to the lack of efficient 
treatment. Chemotherapy is the widely and broadly used treatment, which always uses 
one or more chemotherapeutics to prolong life and or reduce symptoms [1, 2]. 
However, current chemotherapeutic drugs have significant side effects on normal 
healthy cells and tissues if administrated by traditional routes; these are commonly 
myelosuppression, mucositis and alopecia [3]. Therefore, the major challenge in 
chemotherapy is to develop drug delivery systems (DDSs) to deliver 
chemotherapeutic drugs safely and efficaciously without side effects. 
Nano structured DDSs which are able to conjugate a drug have the capability to 
achieve targeted delivery of their content to cancer cells via the enhanced 
permeability and retention effects [4]. Current nano structured DDSs including 
nanoparticles, liposomes and micelles are mainly dispensed orally; through this route 
there are serious existing problems that still cannot be addressed adequately. Such as 
the lack of tissue specificity [5], inefficient drug release at the tumour site and 
endosomal entrapment of nanocarriers, all of these significantly reduce efficacy [6]. 
In order to overcome these barriers, implantable drug delivery (IDD) systems are 
still being developed. IDDSs originated in the 1960s when silicones were applied to 
prolong therapeutic efficiency, this type of delivery was then recognized as a potential 
solution to address the issues associated with oral administration of specific therapies. 
However, little has been reported on the development of nano structured IDDSs, 
which could offer the potential of high drug loading and better cell uptake efficiency. 
Here, we supply an implantable, controllable drug-release silk fibroin (SF) 
nanofibrous DDS, which can not only protect and deliver chemotherapeutic drugs to 
the specific site, but can also achieve controllable drug release therefore minimizing 
side effects.  
Because of the availability of large quantities of the material from the textile 
industry, the ease of processing, controllable degradability and good biocompatibility, 
FDA-approved silk fibroin (SF) has been explored and engineered for numerous 
DDSs [7-11]. The natural polyphenolic compound curcumin (CM) is highly toxic on a 
wide range of cancers [12, 13]. Therefore, in this study CM was used as a drug model 
and incorporated into SF carriers by solution-enhanced dispersion via supercritical 
CO2 (SEDS) forming a nanofibrous matrix for topical cancer treatment. 
2. Materials and methods 
2.1 Materials 
Raw silk fibres of Bombyx mori were purchased from the Jiangsu Wujing China 
Eastern Silk Market Co. Ltd. (China). Curcumin was purchased from International 
Laboratory (USA). CO2 was supplied by the Hong Kong Specialty Gases Co. Ltd. 
(Hong Kong). 1,1,1,3,3,3-Hexafluoroisopropanol (HFIP) was from Jinan Huifengda 
Chemical Co. Ltd. (China). A human colorectal cancer cell line HCT116 and a normal 
human colon mucosal epithelial cell line NCM460 were obtained from the Cell Bank 
of the Chinese Academy of Science (Shanghai, China). All other compounds were of 
analytical purity. 
2.2 Preparation of silk fibroin powder from raw silk fibres 
The raw silk fibres of Bombyx mori were degummed three times to remove 
enveloped sericin in pressurized water at 120°C for 60 min. The degummed SF fibres 
were then immersed in a blend solution that contained calcium chloride, water, and 
ethanol with a molar ratio 1:8:2 for 6 h at 70°C until completely dissolved to obtain 
the regenerated SF solution. Thereafter, the regenerated SF solution was dialyzed 
against distilled water to remove the neutral salts by semi-permeable cellulose tubing 
(molecular weight cutoff 12,000–14,000) and to obtain the pure SF solution. Finally, 
dry SF powders were obtained by spray drying (outlet temperature ~110°C). The 
samples were kept at 4°C for further study. 
2.3 Preparation of curcumin-silk fibroin nanofibrous matrix 
First, CM and SF were mixed (1:19), and then HFIP was added to the required 
concentration (6%). After complete dissolution, the blend solution was ready for 
SEDS (Fig. S1). When the desired pressure and temperature were reached, a steady 
flow of CO2 (in and out of the vessel) was maintained to modulate the system pressure 
at a constant level. The blend solution was delivered into the high-pressure vessel 
simultaneously with the supercritical CO2 flow. Enhanced mixing effect between the 
two flows was achieved using a specially designed nozzle. When the blend solution 
ran out, the fresh CO2 flow was kept running for 2 h to completely remove the 
residual HFIP solvent. The CO2 flow was then stopped, and the high-pressure vessel 
was slowly depressurized to atmospheric pressure. The material was collected on 
filters and vacuum dried at 60°C for 12 h and then kept at 4°C for further 
characterizations. 
2.4 Solvent vapour post-treatment 
After moulding into a round shape with radius 1.5 cm, the prepared CM-SF 
nanofibrous matrices were treated within atmospheres of water vapour, ethanol 
vapour and 25%, 50% and 75% ethanol vapour, separately, followed by drying in the 
hood overnight. Briefly, samples were put into sealed beakers saturated with water 
vapour, ethanol vapour and 25%, 50% and 75% ethanol vapour, and moved into the 
water bath for vapour treatment. The vapour treatment time ranged from 6-12 h, and 
the temperature was set at the range of 25-37
o
C. 
2.5 Surface morphology 
The samples were directly adhered onto an aluminium stub with a thin 
self-adherent carbon film and then coated with a thin layer of gold. The surface 
morphology of the samples was observed via field emission scanning electron 
microscopy (SEM, JEOL, JSM-6490, Japan). 
2.6 Physicochemical characterizations 
The samples were completely mixed with KBr and then pressed into a thin tablet. 
The Fourier transform infrared spectroscopy (FTIR) spectra for the samples were 
obtained using FTIR Perkin Elmer 1720 (Perkin-Elmer, USA) in transmission mode 
with the wave number ranging from 4000 cm
−1
 to 400 cm
−1
. The crystallinity of 
samples was evaluated using an X-ray diffractometer (D8 Advance, Bruker AXS, 
Germany) with Cu Kα (λ = 1.5405 Å) radiation. The measurement was performed in a 
2θ range from 5° to 45° with a 0.02° step size and 10° min−1 scan speed with a 2D 
detector at 40 kV and 40 mA. 
2.7 In vitro drug release study 
Drug release was determined using a modified dialysis bag method. Equal 
amounts of each sample were dispersed in 5 mL of phosphate buffer saline (PBS, pH 
7.4) and placed in a pre-treated dialysis bag (molecular weight: 12,000–14,000 
Daltons). The bag was then placed into 50 mL of PBS and incubated in a water bath at 
37°C and 60 rpm. At specified time points, 1 mL of the solution was removed and 
centrifuged at 10,000 rpm for 10 minutes. The concentration of the supernatant was 
determined by UV spectrophotometer at wavelength 410 nm. The cumulative total 
amount released was calculated in terms of the CM concentration as a function of 
time. 
2.8 Cell culture and proliferation 
HCT116 and NCM460 cells were maintained in Roswell Park Memorial Institute 
(RPMI) 1640 medium (Gibco, Invitrogen) supplemented with 10% FBS (Gibco, 
Invitrogen) and 1% pen-strep (100 U/ml penicillin and 100 μg/ml streptomycin) 
(Gibco, Invitrogen) in a 37 ± 0.2ºC humidified incubator containing 5% CO2, 
respectively. Further, cells were cultured as a monolayer culture and counted using a 
Cellometer Auto T4 (Nexcelom Bioscience LLC, USA). 
2.9 Cellular uptake study 
The cellular uptake efficiency was evaluated by visualizing HCT116 cells in the 
presence of CM-SF matrices. Briefly, 5×10
4
 HCT116 cells were seeded onto cover 
slips (IWAKI, Japan) in 24-well plates overnight to allow cells attach to the cover 
slips. The samples were then added to co-culture for 0.5 and 6 h. After these time 
periods cells were washed with 1× PBS and then fixed with 4% formaldehyde for 1 
min.500 μL of methanol (-20oC) was added to completely remove formaldehyde 
followed by permeabilization with 0.2% Triton X-100 in PBS for 10 min, and washed 
again in PBS. Cells were sealed with 10% BSA. Cell nuclei were stained with 5 μL of 
4’-6’-diamidino-2-phenylindole (DAPI) for 30 min. Stained cells were finally 
mounted onto glass slides and observed using confocal laser scanning microscope 
(CLSM , Leica, TCS SP8). 
2.10 MTS assay 
Both anti-cancer effect of CM-SF nanofibrous matrices on colon cell line 
HCT116 and cytotoxicity on normal cell line NCM460 were evaluated by MTS assay 
using the CellTiter 96
®
AQueous One Solution Cell Proliferation Assay kit (Promega). 
Briefly, samples with different concentrations were prepared and sterilized by UV 
light for 30 min. HCT116 and NCM460 cells were pre-cultivated in the 96-well plates 
(5×10
3
 cells /well) for 24 h, respectively. The cell medium was replaced by the 
samples in complete DMEM (Dulbecco's modified Eagle’s medium) at different 
concentrations on the next day. After 48 h of incubation, the culture medium was 
aspirated and cells were washed with 1× PBS for three times; 200 μL of the MTS 
solution mixed with 1 mL fresh serum free medium was then added for another 4 h of 
reaction. The absorbance values were measured using a Model 680 Microplate Reader 
(Model 680, Bio-Rad, CA) at 490 nm. Cell viability was calculated using Eq. (1) 
below: 
Cell viability (%) =
Absorbance of test cells
Absorbance of control
× 10                             (1) 
Where absorbance of test cells represents the OD490 values of cells treated with 
different experimental groups; and the absorbance of control cells refers to the OD490 
values of non-treated cells in the control groups. 
2.11 Cell cycle and apoptosis measurement 
HCT116 cells (1×10
6
) were co-cultured with control, 5-Fu, and CM-SF 
nanofibrous matrices after ethanol vapour treatment (25
o
C, 6 h and 37
o
C, 12 h, 
respectively) in the medium, Decanted supernatant and collected cells by 
trypsinization, then washed and resuspended in PBS. Cells were then fixed with 
ethanol (70%, -20°C) by vortexing mildly and maintained at 4°C for at least 12 h. 
Thereafter, the cells were pelleted and re-suspended again in 500 μL of PBS, then 50 
μL of 7-ADD was added and incubated at room temperature for 30 min in the dark. 
The stained samples were then recorded with a BD FACS CatoII flow cytometer (BD 
Biosciences, USA). 
For apoptosis analysis, all the cells (1 × 10
6
) treated with control, 5-Fu, and 
CM-SF nanofibrous matrices after ethanol vapour treatment (25
o
C, 6 h and 37
o
C, 12 h, 
respectively) were collected and washed twice with PBS by centrifugation. The cell 
pellet was re-suspended in 500 μL of ice-cold binding buffer. The 5 μL of Annexin 
V-PE and 5 μL of 7-ADD solutions were added into the cell suspension by mild 
vortexing. The samples were then incubated for 5 min in the dark before flow 
cytometric analysis. The stained samples were analysed by flow cytometer. 
2.12 Animal preparation 
A total of 15 female BALB/c nude mice (3-5 weeks old) with body weight 
around 18 ± 2 g were supplied by the Laboratory Animal Center of Sun Yat-Sen 
University (Guangzhou, China). These mice were maintained in a pathogen-free 
environment (23 ± 2°C and 55% ± 5 humidity) on a 12 hour light-12 hour dark cycle 
with food and water supplied ad libitum. Animal care and surgery protocols were 
approved by the Animal Care Committees of Sun Yat-sen University (Guangzhou, 
China). All animals were treated appropriately and used in a scientifically valid and 
ethical manner. To establish CRC allografts for in vivo studies, HCT-116 cells (5 × 
10
5
) were subcutaneously injected into the back of the BALB/c nude mice. After 
several days, a tumour with a volume exceeding 100 mm
3
 formed and the mice were 
randomly separated into 5 groups, three per group according to the volume of tumour 
calculated by Eq. (2) [14]. Tumour volume and mouse weight change ratio (%) were 
calculated using Eq. (3) and (4), respectively. The 5 groups were identified as: (1) and 
(2) implantation with CM-SF nanofibrous matrix (10 mg) after 25
o
C, 6 h and 37
o
C, 12 
h post-treatment, respectively; (3) intraperitoneal injection with 60 mg/kg 5-Fu 
solution in the first day; (4) Oral injection with identical amount of original CM and 
(5) implantation with pure SF nanofibrous matrix and as a control. After 12 days 
observation, all the mice were placed under general anaesthesia by intraperitoneal 
injection of pentobarbital sodium (30 μg/g body wt). Fig. 5 (a) shows the operative 
procedure for the membrane implantation against the tumour. A straight 1 cm skin 
incision was made near the tumour, subcutaneous tissue around the tumour was 
separated so that sufficient space was created for implanting and positioning samples. 
Finally, the incision was sutured so that the tumour could be treated with the 
implanted CM-SF nanofibrous matrix directly. 
V = L × W2                                                         (2)                                              
Tumour volume change ratio (%) = (VN V1⁄ − 1) × 100%                  (3) 
Mouse weight change ratio (%) = (WN W1⁄ − 1) × 100%                   (4) 
Where: V is the volume of tumour, L is the tumour length, W is the tumour width, 
V1and VN is the tumour volume measured at first day and N days after implantation of 
coated drug membrane, W1 and WN are  the mouse weights measured at day 1 and N 
days after treatment of coated drug membrane. 
2.13 H&E staining 
All the tumours separated from the experimental mice were fixed in 10% 
formalin solution, embedded in paraffin, sectioned at 5 μM, and stained with H&E for 
histopathological examination. Images of each tumour were captured at high 
magnification (×50 and ×200 fold) using the Leica DM IRB inverted research 
microscope (Leica Microsystems, Wetzlar, Germany). 
 
Scheme 1. (a) Diagram presents the preparation of CM-SF nanofibrous matrix via 
SEDS; (b) schematic of post-treatment and proposed chemical structure; (c) 
controlled drug release for smart cancer treatment; (d) implantation of the CM-SF 
nanofibrous matrix for in vivo cancer treatment. SEDS: solution-enhanced dispersion 
via supercritical CO2, CM: curcumin; SF: silk fibroin. 
3. Results and discussion 
3.1 Surface morphology and chemical structure after ethanol vapour treatment 
Scheme 1 shows the whole experimental design, to construct nano structured SF 
DDS, SEDS(supplementary Fig. S1). SEDS were modified following previously 
published protocols[15, 16].The surface morphology and fibre diameter are very 
important factors that affect the physicochemical properties and biomedical 
functions[17]. Fig. 1 (a) shows that the CM-SF matrix had a nanofibrous structure 
with fibre diameter < 100 nm. Ethanol vapour treatment was employed to control 
drug release as shown in Fig. 1. The temperature was set at 25-37
o
C, and the 
treatment time was 6-12 h. The surface morphology of sample after ethanol vapour 
treatment was maintained (Fig. 1, (b));  
The chemical structure and composition of CM-SF nanofibrous matrices after 
ethanol vapour treatment shown in Fig. 1, (c). As can be seen, there were no 
significant  changes in the amide II and amide III regions of SF after ethanol vapour 
treatments; however, the amide I region became more predominant with increased 
treatment time and temperature, which indicated that the silk I structure (α-helix 
and/or random coil conformation) became more stable (water-insoluble) when 
exposed to ethanol vapour with higher temperature and longer treatment time. 
 
Fig. 1.Surface morphology and proposed molecular structure of CM-SF nanofibrous 
matrix (a) before and (b) after ethanol vapour treatment; (c) chemical composition and 
in vitro drug release within (d) 2 h and (e) 2 weeks of CM-SF nanofibrous matrix 
under different conditions. (supplementary Fig. S5) 
3.2 In vitro drug release after ethanol vapour treatment 
However, the drug release profiles of CM-SF nanofibrous matrices after ethanol 
vapour treatments were different, that is, the release rate became slower with 
increased treatment time and temperature (Fig. 1, (d) and (e)). The control group 
showed a higher release rate than the treated groups within 2 h, followed by a sharp 
decrease after two weeks. On the other hand, the ethanol vapour treated groups 
remained at a more stable release rate during the two-week experimental period, 
which suggested that ethanol vapour treated CM-SF nanofibrous matrices have 
long-term controllable drug release potential. The results are in agreement with 
previous studies on water-stable silk films with reduced β-sheet content[18]. 
Controlled release of CM from SF-based nanofibrous matrices without inducing 
β-sheet transform could be explained by the formation of a stable silk I structure (Fig. 
1, (b) and (c)). Thus, CM-SF nanofibrous matrices treated by ethanol vapour could 
maintain their nanofibrous structure and a stable long-term release rate without 
inducing β-sheet structural content. 
3.3 Interactions of curcumin-silk nanofibrous matrix between cancer cells 
To investigate the interaction between CM-SF nanofibrous matrices and cancer 
cells, qualitative intracellular uptake assays were performed in Fig. 2, (a), 
fluorescence images of the cancer cells (HCT116) treated with different groups (IC50 
of CM: ~5 μg/mL) for 0.5 h and 6 h were observed. The control group did not exhibit 
any green fluorescence at the measured time. In the CM-SF no treatment group, 
several slightly green fluorescent dots were observed after 0.5 h of treatment and the 
intensity of the green fluorescence increased after 6 h of treatment. By contrast, a lot 
of bright green dots presented in CM-SF nanofibrous matrices after post-treatment 
after 0.5 and 6 h co-culture compared to the no treatment group. Moreover, the 37
o
C, 
12 h treatment group displayed more, brighter dots than the 25
o
C, 6 h treatment group. 
This result indicated that CM-SF nanofibrous matrices after 37
o
C, 12 h of treatment 
had better interaction with cancer cells and CM could rapidly accumulate in the nuclei 
compared to the 25
o
C, 6 h treatment and no treatment groups. The reason could be the 
more stable nanofibrous structure formation in the 37
o
C, 12 h treatment group. Our 
observations were in agreement with a previous study on SF hydrogels, which 
suggested that the nanofibrous structure of SF-derived materials is important for cell 
attachment and cell-matrix interactions [19]. Another possible mechanism of the 
enhanced cell uptake efficiency are illustrated in Fig.2, (b), that is, CM could be 
transported into cancer cells by endocytosis [20]. In a summary, we assumed that 
ethanol vapour treatment facilitated formation of stable nanofibrous structure of SF, 
which could improve the transportation efficiency of CM into cancer cells by 
endocytosis. 
 
Fig. 2. (a) Fluorescence images showing intracellular uptake efficiency of CM-SF 
nanofibrous matrix into cancer cells; (b) diagram displays the mechanism of enhanced 
cellular uptake efficiency. CM: curcumin; SF: silk fibroin. 
3.4 In vitro anti-cancer efficiency of curcumin-silk nanofibrous matrix 
In vitro anti-cancer effects of CM-SF nanofibrous matrices Fig. 3, (a). 5-Fu 
displayed a dose-dependent anti-cancer effect from 0.625-20 μg/mL. The CM-SF 
nanofibrous matrices and CM-DMSO groups exhibited little inhibitory effects<1.25 
μg/mL, and their anti-cancer effects increased sharply when the concentration reached 
5 μg/mL, which confirmed that CM is a highly dose-sensitive medicine. Furthermore, 
both CM-SF nanofibrous matrices and CM-DMSO exhibited a higher anti-cancer 
effect than 5-Fu at a concentration >10 μg/mL. In contrast, the SF control displayed 
no decrease in cell viability at all concentrations. The results were inactive that 
CM-SF nanofibrous matrices have superior anti-cancer potential when the 
concentration is >5 μg/mL. The long term anti-cancer effect was provided in 
supplementary Fig. S6. 
3.5 Cytotoxicity of CM-SF nanofibrous matrix 
The cytotoxicity of CM-SF nanofibrous matrices on normal cells (NCM460) at 
concentrations ranging from 2.5-40 μg/mL was shown in Fig. 3, (b). It was found that 
5-Fu had significant toxicity (~78%) from 2.5 μg/mL, and this toxic effect increased 
with increasing concentration. In contrast, both CM-DMSO and CM-SF nanofibrous 
matrix groups exhibited no toxicity at <5 μg/mL. However, a sharp increase in 
cytotoxicity was observed in the CM-DMSO group (~48%) at 10 μg/mL, but no 
cytotoxicity effect was found in the CM-SF nanofibrous matrix group until 40 μg/mL, 
suggesting that entrapment of CM in SF nanofibrous matrix could reduce the toxic 
effect at a smart treatment concentration range (STCR) (5-20 μg/mL) (Fig. 3, (c)). 
This phenomenon was more obvious in long term cytotoxicity evaluation in 
supplementary Fig. S7. STCR could be due to the entrapped CM being slowly 
released from SF nanofibrous matrix. The pure SF control group displayed no toxicity 
through the test concentration range. In conclusion, incorporating CM into SF 
nanofibrous matrix after ethanol vapour treatment could have a smart treatment 
potential in cancer therapy. 
 
Fig. 3.Smart treatment of cancer cells by CM-SF nanofibrous matrix. (a) In vitro 
anti-cancer effect on HCT116 and (b) cytotoxicity on NCM460; (c) diagram 
illustrates smart treatment concentration range (STCR) of CM-SF nanofibrous matrix. 
CM: curcumin, SF: silk fibroin. 
3.6 Cell cycle arrest by curcumin-silk fibroin nanofibrous matrix 
To further investigate the mechanism for the observed inhibition of colon cancer 
cells by CM-SF nanofibrous matrices, We studied the cell cycle of HCT116 cells 
treated with different groups at IC50 concentration for 24 and 48 h (Fig. 4, (a) and (c)). 
Cancer cells treated with the 5-Fu group displayed high populations (~47%) of cells 
in the S phase at 24 h, which meant that 5-Fu caused significant arrest of cells in the S 
phase. However, this effect was decreased (~43%) for co-cultures at 48 h. This may 
have been due to the decomposition of 5-Fu. Both the 25
o
C, 6 h treated and 37
o
C, 12 
h treated CM-SF nanofibrous matrix groups presented an increased percentage of 
cells in the S phase (~45% and ~66%, respectively) from 24 to 48 h compared to the 
control group (~39% for 48 h), which was due to the continued release of CM from 
the matrices. Overall, the continuous anti-cancer effect of CM-SF nanofibrous 
matrices originated from increased efficacy in arresting cancer cells at the S phase of 
the cell cycle. Our results are agreement with a previous study on human mantle cell 
lymphoma (MCL), which suggested that CM inhibits proliferation of MCL through 
G1/S phase arrest [21]. 
3.7 Induction of cell apoptosis by curcumin-silk fibroin nanofibrous matrix 
Previous research has reported that CM is responsible for inducing apoptosis in a 
variety of cancers including breast, lung, pancreatic and colon [22-24]. To study the 
potential of CM-SF nanofibrous matrices to induce apoptosis in colon cancer cells 
(HCT116), cells were treated with the control, 5-Fu and CM-SF nanofibrous matrices 
(25
o
C, 6 h and 37
o
C, 12 h of treatment, respectively) at IC50 concentration for 24 h 
and 48 h (Fig. 4, (b) and (d)). The 5-Fu group exhibited a similar percentage (~16%) 
of apoptotic cells at 24 h and 48 h experimental points. On the other hand, cancer cells 
treated with CM-SF nanofibrous matrices after ethanol vapour treatment exhibited a 
higher percentage of apoptotic cells compared to the 5-Fu and control groups for the 
whole experimental period. Moreover, the 37
o
C, 12 h treatment group exhibited better 
apoptotic cell induction than the 25
o
C, 6 h treatment group, which was mainly due to 
the improved cellular uptake.  
In summary, the results demonstrated that CM-SF nanofibrous matrices after 
ethanol vapour treatment have higher apoptotic cell induction  which  was 
responsible for the higher anti-cancer effect. Our results were similar to a previous 
study on CM-loaded polymeric micelles for the treatment of colon cancers [25], 
which suggested that the mechanism of inhibition of growth of colon cells was due to 
increased apoptosis associated with cell cycle arrest. The mechanism of cell apoptosis 
induction of CM could be through the inhibition of key anti-apoptotic proteins, Mcl-1, 
Bcl-xL which cause the induction of PARP cleavage [26]. 
 Fig. 4.(a) Qualitative cell cycle and (b) apoptotic progression of HCT116 cells in 
response to control, 5-Fu, and CM-SF nanofibrous matrices after ethanol vapour 
treatment (25
o
C, 6 h and 37
o
C, 12 h, respectively) for 24 h and 48 h. Quadrant Q1, Q2, 
Q3 and Q4 reflect necrosis, late apoptosis, alive and early apoptosis, respectively. (c) 
Quantitative analysis of cell cycle and (d) FACS distributions (%) of apoptotic 
HCT-116 cells in response to different groups at 24 h and 48 h. Total apoptosis 
include late apoptosis plus early apoptosis. All the data was obtained from at least 
three independent experiments. The statistical significance is expressed as ***p 
<0.001, **p <0.01, *p <0.05. 
3.8 In vivo solid tumour treatment 
Implantation of CM-SF nanofibrous matrices for the treatment of solid tumours 
in vivo was performed, Fig. 5, (a) showed the implantation process. Tumour volume 
and body weight of all treated mice were recorded every two days, up to the end of 
the experiment at 12 days. Fig. 5, (b) showed the tumour volume change ratio. The 
results showed that the tumour volume in the SF control, original CM and 5-Fu 
groups increased to at least 2 times by 12 days. On the other hand, The CM-SF 
nanofibrous matrix groups (25
o
C, 6 h and 37
o
C, 12 h treated) showed only a small 
increase in the tumour volume. This was indicative that the CM-SF nanofibrous 
matrices had a more significant anti-tumour effect than the other groups ( i.e. 5-Fu 
group injected intraperitoneally at LD50, original CM group orally administrated and 
the SF control group). Fig. 5, (d and e) confirmed that the implantation of CM-SF 
nanofibrous matrices could treat tumours more effectively than other administration 
routes. Especially, the 37
o
C, 12 h treated group which had the lightest and smallest 
tumours; this was due to their slower drug release and better intracellular uptake effect. 
The body weight change ratio (Fig. 5, (c)) demonstrated that the CM-SF nanofibrous 
matrices would not induce obvious side effects; which was concluded from the 
constant and maintained body weight compared with the other groups. This advantage 
indicated that the CM-SF nanofibrous matrices as implantable devices could treat 
tumours directly showing a better therapeutic efficacy and furthermore, would protect 
patients from side effects. 
3.9 H&E stain analysis 
To study the anti-cancer mechanism, histological analysis of tumour sections was 
performed at the 12
th
day. All the tumours obtained from the experimental mice were 
H&E stained and observed under the optical microscope. The representative areas 
were captured (above: ×50; beneath: ×200). As shown in Fig. 5, (f), tissue necrosis 
was frequently observed for the SF control group, then gradually decreased in the CM 
and 5-Fu groups to rarely in the CM-SF nanofibrous matrices groups (barely seen in 
the 37
o
C, 12 h treated group). The tissue necrosis was attributed to the rapid growth of 
the tumour and ischemia in parts of the tumour [27]. The different anti-cancer 
capability resulted from different levels of apoptosis. As seen in SF control, original 
CM and 5-Fu at LD50 groups, tumours grew rapidly and necrosis was observed in the 
ischemic areas, but few tumour cells were apoptotic. CM-SF nanofibrous matrices 
reduced the rate of growth tumours markedly; tissues had high apoptotic to necrotic 
ratios. This result corresponded to the previous in vitro cell apoptosis analysis (Fig. 4). 
As a result of direct contact with tumour tissue, CM-SF nanofibrous matrices 
presented the slowest growth of tumours. The tumour volume and tumour weight 
were smaller and lower than other groups, fewer necrotic but more apoptotic cells 
were observed. In a summary, this result suggested that implantation of CM-SF 
nanofibrous matrix provided superior induction of apoptosis in vivo. 
 
 
Fig. 5. In vivo investigation of tumour inhibition effects of the CM-SF nanofibrous 
matrices: (a) implantation process of CM-SF nanofibrous matrix into experimental 
mice; (b) tumour growth curves and (c) body weight change ratios of mice treated by 
different groups during the experimental periods; (d) tumour weight; (e) macroscopic 
images and (f) solid tumour histopathology of exposed tumours in experimental mice 
treated with 5-Fu (at LD50 level), SF control (implantation), original CM (orally 
administrated) and CM-SF nanofibrous matrices after ethanol vapour treatment (25
o
C, 
6 h and 37
o
C, 12 h, respectively. 10 mg/mice) after 12 days observation. CM: 
curcumin; SF: silk fibroin; The statistical significance is expressed as **p <0.01, *p 
<0.05. 
4. Conclusions 
In conclusion, CM-SF nanofibrous matrices had improved intracellular uptake, 
this resulted in an enhanced anti-cancer effect. The mechanism could be explained by 
cell cycle arrest in the S phase in association with inducing apoptosis in tumour cells. 
Importantly, CM-SF nanofibrous matrices reduced cytotoxicity at a smart treatment 
concentration range (5-20 μg/mL) due to controlled release properties. Moreover, 
implantation of CM-SF nanofibrous matrices for topical treatment of solid tumour 
showed the smallest tumour volume and lightest tumour weight. It was concluded that 
implantation of CM-SF nanofibrous matrices have smart tumour treatment potential, 
offering an alternative method for novel cancer therapy. 
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